Project Grant K99HL175039

Award Date 8/2/24
Completion Date 7/31/26
Dollars Obligated $212K
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $496,367 to Duke University to conduct research on improving the efficacy of cardiac cell reprogramming therapies. The key objectives are to investigate mechanisms by which a repressor complex inhibits cardiomyocyte gene expression, test whether targeting this repressor complex can enhance the efficacy of microRNA-based reprogramming in...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $156,600 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Texas Southwestern Medical Center (UT Southwestern). The 5-year grant will support research to define the role of the PHF7 protein in driving cardiac reprogramming and improving heart function following a myocardial infarction. Specifically, the project aims to: 1) Characterize...
This Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of the RNA-binding protein RBPMS in regulating cardiac function and disease. The $100,480 award, effective July 15, 2024 through June 30, 2026, will enable the principal investigator to characterize how RBPMS modulates RNA splicing to impact cardiomyocyte contraction, explore the functional...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $243,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Cincinnati's Sponsored Research Services Division. The grant will fund a 2-year project to engineer advanced RNA biodevices that leverage CRISPR and ADAR gene-editing technologies. The goal is to improve the efficiency and specificity of converting resident cardiac fibroblasts into functional cardiomyocytes, in order to boost...
This federal Project Grant award of $2,249,307, provided by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), aims to study the premature maturation arrest of pluripotent-derived cardiomyocytes (PSC-CMs) and develop strategies to overcome this issue. The project will leverage a high-resolution single cell transcriptome map of endogenous cardiomyocyte maturation to identify a critical gene regulatory network underlying the maturation failure in PSC-CMs....
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $134,998 to the J. David Gladstone Institutes in San Francisco to conduct research on the mechanisms that enable cardiac progenitor cells to build the linear heart tube. The award will fund a 2-year research plan that includes: 1) live-embryo imaging and quantitative analysis of cell movements during normal and abnormal heart tube...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund research to generate human induced pluripotent stem cell (iPSC) models of type 2 diabetic cardiomyopathy (T2DCM) and assess the metabolic mechanisms and protective effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors. The total award is $511,864 with a project period from Sep 6, 2024 to Mar 31, 2026. The research will be...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $129,137 to the University of California, Los Angeles (UCLA) to examine the role of long noncoding RNAs (lncRNAs) in hepatic lipid metabolism and their potential implications for cardiovascular and metabolic diseases. The primary objectives are to (1) investigate the influence and mechanism of the lncRNA XTENDR on hepatic lipid homeostasis and sex-specific hepatic...
This $693,261 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Baylor College of Medicine aims to investigate the Hippo-YAP signaling pathway and its role in promoting cardiac regenerative repair following myocardial infarction. The central hypothesis is that gene therapy strategies to knock down Hippo signaling in cardiac tissue can improve cardiac function in mouse models of ischemic heart failure. Key objectives...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $711,039 to the Research Institute at Nationwide Children's Hospital to conduct research on the role of cardiac m6A methyltransferases in the pathogenesis of fetal dilated cardiomyopathy (DCM). The key objectives are to determine the functions of the m6A methyltransferases METTL3 and METTL14 in embryonic mouse myocardium and whether their...

POST-TRANSCRIPTIONAL MECHANISMS OF DIRECT CARDIAC REPROGRAMMING - PROJECT SUMMARY HEART ATTACKS, OR MYOCARDIAL INFARCTIONS (MI), REMAIN A LEADING CAUSE OF DEATH WORLDWIDE. AS ADULT HUMAN HEARTS HAVE LIMITED REGENERATIVE CAPACITY, CARDIOMYOCYTES (CMS) LOST AFTER MI ARE REPLACED BY FIBROTIC SCAR TISSUE, LEADING TO CARDIAC DYSFUNCTION AND OFTEN HEART FAILURE. A PROMISING APPROACH TO REPLACE LOST CMS IS DIRECT REPROGRAMMING OF CARDIAC FIBROBLASTS (CFS) INTO INDUCED CARDIOMYOCYTE-LIKE CELLS (ICMS) USING THE SPECIFIC CARDIAC LINEAGE TRANSCRIPTION FACTORS MEF2C, GATA4 AND TBX5 (MGT). OVER THE LAST DECADE, CONSIDERABLE PROGRESS HAS BEEN MADE IN UNDERSTANDING THE TRANSCRIPTIONAL AND EPIGENETIC REGULATION OF ICM GENERATION. HOWEVER, POST- TRANSCRIPTIONAL PROCESSES, INCLUDING TRANSLATION AND MRNA MODIFICATION, ARE ALSO IMPORTANT TO REGULATE GENE EXPRESSION. POST-TRANSCRIPTIONAL REGULATORS HAVE RECENTLY BEEN SHOWN TO PLAY CRITICAL ROLES IN CELL FATE DETERMINATION, BUT THEIR ROLES IN DIRECT CARDIAC REPROGRAMMING ARE LARGELY UNKNOWN. RECENTLY, DR. XIE IDENTIFIED THE RNA BINDING PROTEIN YBX1 AND THE M6A READER IGF2BP1 AS CRITICAL POST-TRANSCRIPTIONAL BARRIERS TO ICM INDUCTION. EXCITINGLY, UPON REMOVING YBX1, A SINGLE FACTOR, TBX5, COULD SUCCESSFULLY REPROGRAM FIBROBLASTS INTO ICMS. THUS, IN AIM 1, DR. XIE WILL USE CHIP-SEQ AND ATAC-SEQ TO CHARACTERIZE THE MECHANISMS BY WHICH THE INNOVATIVE COCKTAIL TBX5+SIYBX1 GENERATES ICMS. THEN, TAKING ADVANTAGE OF THE REDUCED CARGO SIZE OF THIS COCKTAIL, DR. XIE WILL DEVELOP A CLINICALLY RELEVANT LIPID NANOPARTICLE-MRNA DELIVERY SYSTEM TO ACHIEVE IN VIVO ICM CONVERSION IN A MOUSE MI MODEL. POST-TRANSCRIPTIONAL MRNA M6A METHYLATION IS ANOTHER REGULATOR OF GENE EXPRESSION IMPORTANT IN CELL FATE MAINTENANCE. IN ADDITION TO SERVING AS A BARRIER TO CARDIAC REPROGRAMMING, DR. XIE FOUND THAT THE M6A BINDING PROTEIN, IGF2BP1, FORMED CELLULAR GRANULES IN CFS. SHE, THEREFORE, HYPOTHESIZES THAT IGF2BP1 SEQUESTERS OR OTHERWISE REGULATES THE STABILITY OF M6A MRNAS IN CFS BY REGULATING CELLULAR RNP GRANULE DYNAMICS AND THAT LOSS OF IGF2BP1 LEADS TO A SHIFT IN MRNA METABOLISM PROMOTING CARDIAC FATE CONVERSION. TO TEST THESE HYPOTHESES, AIM 2 IS TO IDENTIFY M6A ALTERNATIONS ASSOCIATED WITH ICM GENERATION, MAP PRECISE RNA BINDING SITES OF IGF2BP1 AND ELUCIDATE THE UNDERLYING MECHANISM THROUGH WHICH IGF2BP1-MEDIATED CELLULAR GRANULE FORMATION REGULATES THE INDUCTION OF ICMS. THE PROPOSED WORK WILL NOT ONLY FILL CRITICAL GAPS IN OUR MECHANISTIC UNDERSTANDING OF HOW POST-TRANSCRIPTIONAL REGULATION IMPACTS CARDIAC FATE CONVERSION, BUT ALSO ADVANCE ICM REPROGRAMMING CLOSER TO THERAPEUTIC APPLICATION THROUGH THE DEVELOPMENT OF AN LNP-MRNA DELIVERY SYSTEM. WITH AN EXCELLENT MENTORING TEAM AND A STIMULATING RESEARCH ENVIRONMENT AT UNC CHAPEL HILL, DR. XIE WILL LEARN CUTTING-EDGE TECHNIQUES AND HONE HER PROFESSIONAL SKILLS, WHICH WILL PROVIDE A SOLID FOUNDATION FOR HER FUTURE RESEARCH IN STUDYING THE MECHANISMS OF CARDIOVASCULAR DISEASE AND TO USE INSIGHTS FROM THIS WORK TO DEVELOP NOVEL THERAPIES TO IMPROVE PATIENTS' LIVES. THIS K99/R00 AWARD WILL SUPPORT THE DEVELOPMENT OF HER UNIQUE AND COMPREHENSIVE RESEARCH PROGRAM AND CATALYZE THE TRANSITION TO INDEPENDENCE.

Posted 8/2/24, 12:00 AM